Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

March 28, 2015 11:08 AM ET


Company Overview of NGM Biopharmaceuticals, Inc.

Company Overview

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, discovers and develops transformational biologics for the treatment of cardio-metabolic diseases, hepatic diseases, and cancers. It offers NGM282, a phase 2 clinical development products that is used for the treatment of gastric bypass surgery on metabolic and bile acid-related diseases. The company also develops novel drug candidates for the treatment of Type 2 diabetes and obesity. In addition, it offers various drug discovery programs that include enteroendocrine cells, beta-cell regeneration, and intestinal microbiome programs. The company has strategic partnerships with MedImmune/AstraZeneca, Daiichi Sankyo, and JDRF. NGM Biopha...

630 Gateway Boulevard

South San Francisco, CA 94080-7014

United States

Founded in 2007





Key Executives for NGM Biopharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 54
Age: 41
Founder, Chief Scientific Officer and Director
Age: 51
Chief Financial Officer
Chief Medical Officer and Vice President
Compensation as of Fiscal Year 2014.

NGM Biopharmaceuticals, Inc. Key Developments

NGM Biopharmaceuticals Announces Management Appointments

NGM Biopharmaceuticals, Inc. announced that Jeff Jonker has been named President and David Woodhouse, Ph.D., has joined the company as Chief Financial Officer, effective immediately. Prior to joining NGM, Mr. Jonker was the Senior Vice President, Corporate and Business Development at Theravance Biopharma and Theravance, Inc. He previously served as the Chief Business Officer of Satori Pharmaceuticals and the Vice President of Business Development and Corporate Strategy for Gloucester Pharmaceuticals, prior to its acquisition by Celgene. Dr. Woodhouse joins NGM from Goldman Sachs, where he was Managing Director and Co-Head of U.S. Biotechnology Investment Banking. As a member of Goldman's healthcare investment banking group for nearly 13 years in the New York and San Francisco offices, Dr. Woodhouse's responsibilities included corporate finance and mergers and acquisitions (M&A) advice for the biotechnology, specialty pharma and diagnostics industries.

NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics

NGM Biopharmaceuticals, Inc. and Merck announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas. This agreement will become effective upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The collaboration includes multiple drug candidates currently in preclinical development at NGM, including NP201, which is being evaluated for the treatment of diabetes, obesity and nonalcoholic steatohepatitis (NASH). NGM will lead the research and development of the existing preclinical candidates and have the autonomy to identify and pursue other discovery stage programs at its discretion. Merck will have the option to license all resulting NGM programs following human proof of concept trials. If Merck exercises this option, Merck will lead global product development and commercialization for the resulting products, if approved. Under the terms of the agreement, Merck will make an upfront payment to NGM of $94 million and will purchase a 15% equity stake in NGM for $106 million at a price per share that represents a 20% premium to NGM’s most recent financing. Merck will commit up to $250 million to fund all of NGM’s efforts under the initial five-year term of the collaboration, with the potential for additional funding if certain conditions are met. Prior to Merck initiating a Phase 3 study for a licensed program, NGM may elect to either receive milestone and royalty payments or, in certain cases, to co-fund development and participate in a global cost and revenue share arrangement of up to 50%. The agreement also provides NGM with the option to participate in the co-promotion of any co-funded program in the United States. Merck will have the option to extend the research agreement for two additional two-year terms.

NGM Biopharmaceuticals, Inc. - Special Call

To discuss about multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas with Merck

Similar Private Companies By Industry

Company Name Region
Microban Products Company United States
MPS BioPharm United States
PharmSelex United States
Palmetto Biomedical, Inc. United States
KMS Industries, Inc. United States

Recent Private Companies Transactions

Private Placement
February 23, 2015
Private Placement
October 9, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NGM Biopharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at